{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-279038","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.699625+00:00","generated_at":"2026-05-29T02:53:34.327613+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE","bullets":["ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).","Patients on ANX005 ~2x more likely to be in better health on GBS-Disability Scale at week 8 (p=0.0459).","Fewer ANX005 patients required mechanical ventilation (15/79 vs 32/79, p=0.022); 12 fewer median days on ventilation and in ICU.","Planned U.S. Biologics License Application submission for ANX005 in GBS in first half 2025.","Study used propensity-score matching between Phase 3 patients (n=79) and IGOS global registry patients (n=79)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-279038","json":"https://secwatch.observer/filing/0001193125-24-279038.json","markdown":"https://secwatch.observer/filing/0001193125-24-279038.md","text":"https://secwatch.observer/filing/0001193125-24-279038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524279038/0001193125-24-279038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524279038/d909577d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:53:34.327613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}